Cellular Response to an Antisense-mediated Shift of Bcl-x Pre-mRNA Splicing and Antineoplastic Agents
Open Access
- 1 December 2002
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (51), 49374-49382
- https://doi.org/10.1074/jbc.m209236200
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugsLeukemia Research, 2002
- Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780Journal of Clinical Oncology, 2001
- Bcl‐XL Antisense Sensitizes Human Colon Cancer Cell Line to 5‐FluorouracilJapanese Journal of Cancer Research, 2000
- Apoptosis in cancerCarcinogenesis: Integrative Cancer Research, 2000
- Apoptosis and cancer drug targetingJournal of Clinical Investigation, 1999
- Dysregulation of Apoptosis in CancerJournal of Clinical Oncology, 1999
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Targeting cancer cell death with a bcl-xS adenovirusSpringer Seminars in Immunopathology, 1998
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Expression of bcl-xL can confer a multidrug resistance phenotypeBlood, 1995